Eribulin/encequidar (Athenex)

N/A

Report date: 2024/04/17 20:05:34

Base Information

Drug NameEribulin/encequidar (Athenex)
Drug Alias NameEncequidar/eribulin (Athenex)Eribulin + HM-30181A (Athenex)Eribulin oral/encequidar oral (Athenex)Eribulin ORA (Athenex)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitorsTubulin inhibitorsP-glycoprotein 1 inhibitors
TargetsTubulinP-glycoprotein 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Eribulin MesylateEncequidar mesylate
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAthenex Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHealth Hope Pharma
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A